The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients.
about
Management of immunosuppressant agents following liver transplantation: Less is moreManagement of Hepatitis C Post-liver Transplantation: a Comprehensive ReviewClinical Advances in Fibrosis Progression of Chronic Hepatitis B and CHepatitis C and liver transplantationFibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantationManagement of hepatitis C infection before and after liver transplantationHuman monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzeesMRI-guided biopsy to correlate tissue specimens with MR elastography stiffness readings in liver transplants.Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.Treatment modalities for hypersplenism in liver transplant recipients with recurrent hepatitis C.Change in platelet count in patients with hypersplenism subjected to liver transplantation.Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy.Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles.Retransplantation for graft failure in chronic hepatitis C infection: a good use of a scarce resource?Outcomes among older adult liver transplantation recipients in the model of end stage liver disease (MELD) eraPretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantationAn extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantationAntifibrotic agents for liver disease.Rejection under alpha interferon therapy in liver transplant recipients.Therapeutic management of recurrent hepatitis C after liver transplantation.Donor Factors Including Donor Risk Index Predict Fibrosis Progression, Allograft Loss, and Patient Survival following Liver Transplantation for Hepatitis C VirusTransjugular intrahepatic portosystemic shunt in liver transplant recipients.Perioperative blood transfusion affects hepatitis C virus (HCV)-specific immune responses and outcome following liver transplantation in HCV-infected patients.Non-invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence.Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation.Living donor liver transplantation for hepatitis C.Liver Support With Albumin Dialysis Reduces Hepatitis C Virus Viremia and Facilitates Antiviral Treatment of Severe Hepatitis C Virus Recurrence After Liver Transplantation.Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review.Sinusoidal endotheliitis as a histological parameter for diagnosing acute liver allograft rejectionOutcome after liver re-transplantation in patients with recurrent chronic hepatitis C.Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.Validation of the FIB-4 index for evaluation of fibrosis in patients with recurrent hepatitis C after living donor liver transplantation: A single center experience.Mycophenolate mofetil may induce prolonged severe anemia during pegylated-interferon/ribavirin/simeprevir therapy in liver transplant recipients.High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation.Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation.An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin.Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients.Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C.Recurrence of hepatitis C after liver transplantation.
P2860
Q26770033-2B50E94D-5A17-417F-AA35-0F7AEF3C7055Q26781741-E1102D34-C95F-4C25-8AE3-432E9C0C6452Q26781789-BE654F7C-6633-43DB-8010-D51E9206B374Q27490388-6B121951-1343-4AB8-90C8-552EB593A4B7Q28076406-DF565DA9-C39D-41E9-BB0F-44FACC95A4D9Q28081250-87755B68-15E0-4EBD-B067-2D5C6AAD42D3Q28483065-3D8CE963-264A-4DB5-B2E3-46A978C903B5Q30449830-80EEC219-BA5F-417F-B83E-B3B8D1BB0DF7Q33374906-E1BCEC24-F835-43FE-934B-AA538958F40AQ33386811-FA9F93A2-4390-4E46-9E47-7B52495EF1F6Q33397373-89483E1A-9E84-472C-A574-48F1EACF4FBEQ33800146-BDFA74C1-FAB6-4141-8C60-22BD4291AE46Q34232434-AC016A94-B7FC-4E7A-8C7A-F8ADF0692B29Q34246962-4C3A3C2C-C08C-4D87-920F-109392436296Q34362803-E70802B3-74E0-46B4-BF22-5F285863961EQ34625761-940542A4-E00E-4C40-94B4-949A4DCAB27EQ35173005-0FE9CC11-0DE4-463D-915C-5F0474C26B1FQ36376477-F8448821-7AAC-490A-BDAA-499012DC1B91Q36709673-C65899F8-3F55-4D47-A0DC-D5DBA537187CQ36758660-7CE427A3-1C10-4100-9A42-6F2F09E7C328Q37131609-6A13AB82-7448-4C17-8B10-D19FE7AB07FDQ37174075-D9D8D7BF-07BE-434B-AA3D-26B4A69EDA24Q37623515-7C5161F5-D05A-4B12-A48E-B908D539AB1DQ37868672-63B1D8E9-CEC2-446A-9754-FE3485D58932Q37973516-C40B9063-4226-4334-AC18-3CA39F73B038Q38050972-9ED9D165-178D-48AC-A608-CC0501BB3A59Q38439220-2BF8D2D5-83E2-4D2B-BB13-196043A3AB62Q38874771-35CD5623-9767-4D7C-8038-92EEA1108B7DQ38949181-6881D1BD-A32C-4850-9CFE-F19A31F8A83AQ40196672-F670359F-31F3-458B-872C-2B2E0931D708Q40309524-209089E6-AF0D-4DAF-B7EE-16A8ED0943F9Q40904119-2F5EA9CD-1B6B-4E5F-971E-FC878BC49D13Q41241023-8566C5DB-C2F1-41C5-826B-A39F1418B197Q41412067-B80191A9-F8AB-4695-839F-FDEC89228249Q41673507-8640E867-5C3A-453A-9BCD-8C25DEF272CFQ42028499-BFEB88F1-11FB-4040-9A11-E0CC67FEE10DQ42148776-E43DD34E-4584-4A46-AE0E-7D88BAB7D163Q42228443-F5889A56-6A3B-4F95-9C1C-5D597A868C2AQ42262646-81345C6F-A26A-464D-9E01-9E97EEB9E4A0Q42406576-984392B8-2A37-467C-ACC9-EF590C9C48AA
P2860
The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The natural history and outcom ...... s C virus-infected recipients.
@ast
The natural history and outcom ...... s C virus-infected recipients.
@en
type
label
The natural history and outcom ...... s C virus-infected recipients.
@ast
The natural history and outcom ...... s C virus-infected recipients.
@en
prefLabel
The natural history and outcom ...... s C virus-infected recipients.
@ast
The natural history and outcom ...... s C virus-infected recipients.
@en
P356
P1476
The natural history and outcom ...... s C virus-infected recipients.
@en
P2093
Edward Gane
P304
P356
10.1053/JLTS.2003.50248
P577
2003-11-01T00:00:00Z